Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY, Dec 3-5, 2024.
波士頓，2024年11月25日，環球新聞社報道--cue biopharma，Inc.（納斯達克：CUE），一家開發新型治療生物製品以選擇性地激活和調節特定疾病t細胞治療癌症和自身免疫疾病的臨床階段生物製品公司，今天宣佈將參加將於2024年12月3日至5日在紐約舉行的派傑投資第36屆醫療保健大會上的一場未播放的爐邊討論。
During the fireside discussion, Cue Biopharma will provide an overview highlighting recent clinical and preclinical program updates as well as strategic business and partnering model objectives.
在爐邊討論期間，cue biopharma將概述最近的臨床和臨床前計劃更新以及戰略業務和合作夥伴模式目標。
Presentation Details
Date and Time: Wednesday, December 4, 2024, from 9 a.m. EST – 9:25 a.m. EST
Webcast Link:
Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma
報告詳情
日期和時間：2024年12月4日，從美國東部時間上午9點至上午9點25分。
網絡廣播鏈接：
Presenter: Daniel Passeri萬.Sc., J.D., chief executive officer, Cue Biopharma
A live and archived webcast of the fireside discussion will be available on the Events page in the Investors and Media section of the Company's website at . The webcast will be archived for 30 days.
公司網站的投資者與媒體部分的事件頁面將提供有關圍爐討論的現場直播和存檔網絡廣播。該網絡廣播將存檔30天。
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
關於cue biopharma
Cue生物製品是一家處於臨床階段的生物製品公司，正在開發一種新型類注射生物製品，可選擇性地干預和調節病特異性t細胞，直接作用於患者體內。該公司專有的平台Immuno-STAt（t細胞的選擇性靶向和改變）以及生物製品旨在通過選擇性調節病特異性t細胞，而無需進行全面系統性免疫調節，利用體內免疫系統的治癒潛力。
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
總部位於馬薩諸塞州的波士頓，我們由一支經驗豐富的管理團隊和獨立的董事會領導，擁有在免疫學、免疫腫瘤學以及蛋白質生物製品的設計和臨床開發方面的深厚專業知識。
For more information please visit and follow us on X and LinkedIn.
Marie Campinell 高級總監，企業傳訊 Cue Biopharma, Inc.
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
投資者聯繫方式
Marie Campinell
高級董事，企業通信
cue biopharma，全球貨幣
mcampinell@cuebiopharma.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
媒體聯繫
Jonathan Pappas
通信-半導體
jpappas@lifescicomms.com
譯文內容由第三人軟體翻譯。
